Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Applebaum

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Journal of Pediatric Surgery|February 1, 1995
Diagnosis, management, and outcome of cervicofacial teratomas in neonates: a Childrens Cancer Group studyR G Azizkhan, G M Haase, H Applebaum, et al.
Journal of Neuroengineering and Rehabilitation|September 12, 2020
Users with spinal cord injury experience of robotic Locomotor exoskeletons: a qualitative study of the benefits, limitations, and recommendationsDominique Kinnett-Hopkins, Chaithanya K Mummidisetty, Linda Ehrlich-Jones, et al.
Clinical Breast Cancer|August 14, 2010
A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01)Sara A Hurvitz, Heather J Allen, Rebecca L Moroose, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Journal of Pediatric Surgery|February 1, 1995
Diagnosis, management, and outcome of cervicofacial teratomas in neonates: a Childrens Cancer Group studyR G Azizkhan, G M Haase, H Applebaum, et al.
Journal of Neuroengineering and Rehabilitation|September 12, 2020
Users with spinal cord injury experience of robotic Locomotor exoskeletons: a qualitative study of the benefits, limitations, and recommendationsDominique Kinnett-Hopkins, Chaithanya K Mummidisetty, Linda Ehrlich-Jones, et al.
Clinical Breast Cancer|August 14, 2010
A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01)Sara A Hurvitz, Heather J Allen, Rebecca L Moroose, et al.
Pageof 5